Objective: To test the hypothesis that once-daily treatment with fluticasone propionate is as effective as twice-daily treatment in children with well controlled asthma. Design: Multicentre ...

Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a ...

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates ...

Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary ...

The latest clinical guidelines from the American College of Gastroenterology aim to improve the diagnosis and treatment of ...

today announced preliminary unaudited XHANCE® (fluticasone propionate) net product revenue of $22.4 million for the three months ended December 31, 2024. “Our preliminary unaudited fourth ...

In the INS class, fluticasone propionate (Flonase; GlaxoSmithKline (GSK)) reached blockbuster status, but was largely replaced by generic entrants after its loss of exclusivity in 2006.

The Chippenham-based company has an asthma drug on the market called Flutiform (fluticasone propionate/ formoterol fumarate) which is sold by Mundipharma, a generic version of GlaxoSmithKline's ...

fluticasone propionate and short-acting beta agonist (SABA) albuterol sulfate. The drug – delivered using a proprietary Teva inhaler – could become the first ICS/SABA for both the adult and ...

Flonase (fluticasone propionate) is a common nasal corticosteroid spray for treating occasional allergy symptoms. These types of sprays reduce mucus production, swelling, and nasal congestion.